Search

everythinglearnresearchcommunity

for

Search:↓

Folliculin deficiency causes problems with cell division and positioning due to disrupted RhoA signaling and interaction with p0071.

miR-3606-3p reduces skin fibrosis by blocking key signaling pathways.

The new assay can help develop products for hair re-growth.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

SIG-1451 could be a promising new treatment for atopic dermatitis.

sPLA2-IIA increases growth in hair follicle stem cells and cancer cells, suggesting it could be targeted for hair growth and cancer treatment.

ILK is essential for proper hair follicle development and structure.

The lanceolate hair-J mutation in mice helps understand human hair disorders like Netherton's syndrome.

Special immune cells called Tregs can help prevent lung scarring by blocking a specific growth factor.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.

People with alopecia areata have fewer IL-10 producing immune cells, which might contribute to the condition.

Higher CRHR1 levels in AA patients lead to increased inflammation.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Activating TLR3 may help produce retinoic acid, important for tissue regeneration.

Alarmin cytokines are key in controlling skin immunity and inflammation.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

NEDD4 and NEDD4L help control intestinal stem cells and prevent tumors by breaking down the LGR5 receptor.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Lenalidomide helps hair follicle stem cells turn into melanocytes, which may improve repigmentation in vitiligo.

Removing Ctip2 in skin cells causes skin inflammation similar to atopic dermatitis.

Measuring 24-OHase induction helps identify defects in vitamin D processing and predict treatment response.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

LRIG1 is linked to better survival in Merkel cell carcinoma.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.